Skip to main content
. 2017 Jul 18;60(10):1951–1960. doi: 10.1007/s00125-017-4346-8

Table 1.

Selected characteristic of study participants, the Rotterdam Study

Characteristic Participants (n = 3639) Missing values, n (%)
Age, years 66.9 ± 9.6 0 (0)
Age of menopause, years 50.0 ± 4.4 0 (0)
Time since menopause, years 15.0 (15.7) 0 (0)
Pregnanciesa, n 2.2 ± 1.4 306 (8.4)
Age at menarche, years 13.4 ± 1.7 88 (2.4)
Current smokers, n (%) 720 (19.8) 39 (1.1)
Alcohol intake, g/day 2.9 (13.7) 971 (26.7)
Education level, n (%)
  Low 547 (15.0) 26 (0.7)
  Intermediate 2711 (74.5) 0 (0)
  High 381 (10.5) 0 (0)
BMI (kg/m2) 27.0 ± 4.4 237 (6.5)
Waist circumference, cm 89.2 ± 11.6 357 (9.8)
Prevalent CVD, n (%) 245 (6.7) 3 (0.1)
Physical activity, MET-h/week 82.8 ± 50.5 463 (12.7)
Total oestradiol, pmol/l 30.2 (36.3) 377 (10.4)
Total testosterone, nmol/l 0.82 (0.54) 365 (10.0)
SHBG, nmol/l 60.7 (39.2) 378 (10.4)
DHEAS, nmol/l 1649 (1533.8) 360 (9.9)
DHEA, nmol/l 9.6 (8.7) 442 (12.1)
Androstenedione, nmol/l 2.3 (1.4) 380 (10.4)
TSH, mU/l 2.0 (1.7) 377 (10.4)
Hormone replacement therapy, n (%) 95 (2.6) 121 (3.3)
Insulin, pmol/l 68 (47) 330 (9.1)
Glucose, mmol/l 5.4 ± 0.6 345 (9.5)
CRP, mg/ml 1.6 (2.7) 378 (10.4)
Total cholesterol (mmol/l) 6.0 ± 1.0 259 (7.1)
LDL-C, mmol/l 5.1 ± 1.2 336 (9.2)
HDL-C, mmol/l 1.5 ± 0.4 294 (8.1)
Lipid-lowering medication use, n (%) 502 (13.8) 121 (3.3)
TG, mmol/l 1.3 (0.75) 293 (8.1)
Systolic BP, mmHg 139.1 ± 21.6 194 (5.3)
Antihypertensive medications, n (%) 1126 (30.9) 121 (3.3)
Incident type 2 diabetes, n (%) 348 (9.6) 0 (0.0)

Data are means ± SD or median (interquartile range), or n (%) where indicated

The values (mean, median, SD, number, percentage) presented for every characteristic with missing information represent the values after the multiple imputation

aOf at least 6 months’ duration

DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate